1. Home
  2. RGNX

RGNX

REGENXBIO Inc.

Logo REGENXBIO Inc.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-23-2024 1:31pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Founded: 2008 Country:
United States
United States
Employees: N/A City: ROCKVILLE
Market Cap: 769.5M IPO Year: 2015
Target Price: $40.56 AVG Volume (30 days): 744.9K
Analyst Decision: Strong Buy Number of Analysts: 10
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -6.02 EPS Growth: N/A
52 Week Low/High: $11.83 - $28.80 Next Earning Date: 05-01-2024
Revenue: $90,242,000 Revenue Growth: -19.94%
Revenue Growth (this year): 51.02% Revenue Growth (next year): 75.66%

Share on Social Networks: